On Thursday, Biological E said that it will submit final data for its Covid-19 vaccine Corbevax until the end of November. The news comes only two days after the big pharmaceutical firm applied to the Drugs Controller General of India for permission to start a phase 3 clinical study of the Covid vaccine Corbevax. For people who have been completely vaccinated with Covishield or Covaxin vaccinations, the firm has applied for clearance as a single booster dosage.
The Central Drugs Standard Control Organisation (CDSCOSubject )’s Expert Committee (SEC) on COVID-19 may examine the issue at its next meeting.
The phase 2/3 clinical trials of Corbevax are underway and the results are likely to be declared this month.
Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane and facilitates virus entry. The body’s own cells stimulate the immune system of the body to produce antibodies to protect against the infection.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…